Medical Devices US

US Diabetes Care Devices Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

US Diabetes Care Devices Market Industry Trends and Forecast to 2034: Segmented by (Product type, Device Type, Delivery Type, Distribution Channel, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $18.59 Bn Placeholder estimate
Estimate 2025 $19.31 Bn 40.4% of the global market
Projected 2034 $27.25 Bn 41.1% Adds $7.94 Bn over 9 forecast years
CAGR 2025–2034 3.9% Faster than 11% of 173 Medical Devices markets here
Key players 10 +5
  • US is 40.43% of the global market.
  • In North America, the largest is US (this report) at $19.31 Bn.
  • Fastest growing: Canada at 5.9% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$7.94 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Diabetes Care Devices Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $18.59 Bn — —
2025 (base) $19.31 Bn +$725.0 Mn —
2026 (forecast) $20.07 Bn +$753.3 Mn +3.9%
2027 (forecast) $20.85 Bn +$782.7 Mn +8%
2028 (forecast) $21.66 Bn +$813.2 Mn +12.2%
2029 (forecast) $22.51 Bn +$844.9 Mn +16.5%
2030 (forecast) $23.39 Bn +$877.8 Mn +21.1%
2031 (forecast) $24.30 Bn +$912.1 Mn +25.8%
2032 (forecast) $25.25 Bn +$947.6 Mn +30.7%
2033 (forecast) $26.23 Bn +$984.6 Mn +35.8%
2034 (forecast) $27.25 Bn +$1.02 Bn +41.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Diabetes Care Devices Market Analysis at a glance
Market size, 2025$19.31 Bn placeholder estimate
Forecast, 2034$27.25 Bn placeholder estimate
Growth (CAGR), 2025–20343.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct type, device type, delivery type and distribution channel (see all)
Key playersMedtronic, Abbott Laboratories, Dexcom, Inc., Roche Diabetes Care, Novo Nordisk A/S and 5 more (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials297 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 9 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Diabetes Care Devices Market Analysis Executive Summary

The Diabetes Care Devices Market encompasses a range of medical devices specifically designed to assist individuals in managing their diabetes effectively. This includes devices for monitoring blood glucose levels, administering insulin, and overall diabetes management. The market is crucial for helping patients avoid complications associated with diabetes, such as kidney failure, heart disease, and vision loss. The increasing prevalence of diabetes globally, driven by factors such as rising obesity rates and sedentary lifestyles, is propelling the demand for these devices.

Key segments within the diabetes care devices market include blood glucose monitoring devices, such as self-monitoring blood glucose meters and continuous glucose monitors, as well as insulin delivery devices like insulin pens and pumps. The integration of smart technology into these devices is transforming diabetes management, making it more convenient and effective for patients. Additionally, the market is characterized by a competitive landscape with major players like Abbott Laboratories, Medtronic, and Becton, Dickinson and Company, continuously innovating to enhance their product offerings and improve patient outcomes.

Bar chart: US Diabetes Care Devices market size, 2024–2034, placeholder estimates. $18.59 Bn in 2024, $19.31 Bn in 2025 and $27.25 Bn in 2034, 3.9% CAGR.
US Diabetes Care Devices market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Diabetes Care Devices Market Dynamics

Market Growth Drivers

Driving factors in the diabetes care devices market are primarily linked to the escalating prevalence of diabetes worldwide. This increase is largely attributed to rising obesity rates, unhealthy dietary habits, and sedentary lifestyles, which contribute to a higher incidence of diabetes, particularly type 2. According to the National Center for Biotechnology Information (NCBI), if current trends continue, a significant portion of the global population will be overweight or obese by 2035, leading to a surge in diabetes cases. As the demand for effective diabetes management solutions grows, so does the need for advanced diabetes care devices, such as continuous glucose monitoring systems, insulin pumps, and smart insulin pens, which enhance patient outcomes and improve the quality of life for individuals living with diabetes.

Technological advancements are also a crucial driver of market growth. Innovations in diabetes care devices have led to the development of more accurate, convenient, and efficient tools for monitoring blood glucose levels and administering insulin. The integration of smart technology into insulin delivery devices has transformed diabetes management, making it easier for patients to track their health and adhere to treatment plans. Additionally, the increasing adoption of telemedicine and remote monitoring technologies allows healthcare providers to offer more personalized care, further driving the demand for diabetes care devices.

Market Restraints

Despite the positive outlook, the market faces challenges such as limited access to healthcare in rural areas and high costs associated with diabetes care devices. These factors can hinder the adoption of necessary technologies, particularly in underdeveloped regions. However, the overall growth potential remains strong, driven by rising awareness of diabetes management, government initiatives to promote healthy lifestyles, and the continuous innovation of diabetes care devices. As the market evolves, it is expected to witness significant advancements that will enhance the management of diabetes and improve patient outcomes.

Competitive Landscape for Diabetes Care Devices Market in US

Key Players

Recent Developments:

In 2022, Dexcom launched the Dexcom G7 continuous glucose monitoring (CGM) system in the US and several European countries. The G7 is 60% smaller than the previous G6 model and features a 30-minute warm-up period.

In 2022,Insulet received FDA clearance for its Omnipod 5 automated insulin delivery system, the first tubeless, wearable system integrated with a smartphone app and compatible with multiple blood glucose devices.

In 2022,Tandem Diabetes Care launched the t:slim X2 insulin pump with Control-IQ technology in several international markets, offering automated insulin delivery based on Dexcom CGM readings.

In 2025, Abbott received CE Mark for its FreeStyle Libre 3 CGM system in Europe, providing real-time glucose readings every minute with improved accuracy compared to fingerstick measurements.

Medtronic launched the MiniMed 780G insulin pump system with advanced hybrid closed-loop technology in several countries, automatically adjusting insulin delivery based on Medtronic CGM data.

In 2025, Eli Lilly and Dexcom announced a strategic collaboration to integrate Dexcom CGM data into Lilly's connected insulin pen solutions, aiming to provide a more comprehensive diabetes management platform

Healthcare Policies and Regulatory Landscape for Diabetes Care Devices Market in US

Diabetes Care Devices in the US: rules, payment and research

The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 297 studies on Diabetes Care Devices that are recruiting, active or about to start in the US.⁠[3] Diabetes (adults): 12.5% of adults in 2022, the latest WHO figure for the US.⁠[4]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 9 Nov 2026.

[4] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.

The healthcare policies and regulatory landscape for the diabetes care devices market is characterized by a framework designed to ensure the safety, efficacy, and accessibility of these essential medical devices. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) set stringent guidelines for the approval and monitoring of diabetes care devices. Manufacturers must demonstrate the safety and effectiveness of their products through comprehensive clinical trials and testing before they can enter the market. This regulatory oversight is crucial for maintaining consumer trust and ensuring that patients have access to reliable and effective diabetes management tools.

In addition to regulatory requirements, reimbursement policies significantly influence the adoption of diabetes care devices. In many regions, including those with universal healthcare systems, government support for diabetes management technologies can enhance patient access to necessary devices. Conversely, limited reimbursement for advanced diabetes technologies can hinder their uptake in certain markets. Advocacy from patient groups and healthcare organizations is vital in pushing for broader coverage and reimbursement policies that recognize the value of diabetes care devices in improving patient outcomes.

Furthermore, global initiatives aimed at increasing awareness of diabetes and promoting healthy lifestyles are also impacting the regulatory landscape. Organizations such as the World Health Organization (WHO) and the International Diabetes Federation (IDF) work to raise awareness about diabetes management and the importance of using advanced technologies. These initiatives help to educate healthcare providers and patients, fostering an environment that encourages the adoption of diabetes care devices. Overall, the regulatory landscape is evolving to support the integration of innovative technologies into diabetes management, ultimately aiming to improve patient care and outcomes on a global scale.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Diabetes Care Devices right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Diabetes Care Devices in context

The US compared

  • Diabetes (adults, WHO): 12.5% of adults (2022). World: 14.1% of adults (2022).[1]
  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[2]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[3]

[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the Diabetes Care Devices market in the US?
Placeholder estimate: about $19.31 Bn in 2025, rising to about $27.25 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Diabetes Care Devices market in the US growing?
Placeholder estimate: about 3.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Diabetes Care Devices market report cover?
The report splits the market by product type (Blood Glucose Monitoring Devices, Insulin Delivery Devices), device type (Self-monitoring, Diagnostic), delivery type (Pumps, Pen, Syringes, Injectors and more) and distribution channel (Institutional Sales, Retail Sales).
Who are the key players in the Diabetes Care Devices market?
Key players include Medtronic, Abbott Laboratories, Dexcom, Inc., Roche Diabetes Care, Novo Nordisk A/S and Ascensia Diabetes Care, among 10 companies the report profiles.
What is driving the Diabetes Care Devices market?
Driving factors in the diabetes care devices market are primarily linked to the escalating prevalence of diabetes worldwide. This increase is largely attributed to rising obesity rates, unhealthy dietary habits, and sedentary lifestyles, which contribute to a higher incidence of diabetes, particularly type 2.
Who regulates Diabetes Care Devices in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Diabetes Care Devices are running in the US?
297 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 9 Nov 2026.
What does WHO report for the US?
Diabetes (adults): 12.5% of adults in 2022, the latest WHO figure. Source: WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 17 Nov 2026.
Back to Catalogue

Related Medical Devices reports in US

See all

Related on diabetes

See the topic